<DOC>
	<DOC>NCT01228565</DOC>
	<brief_summary>The aim of this randomized trial is to compare the rate of radio-dermatitis grade 2+ (NCI-CTC V3.0) in patients receiving radiotherapy+Erbitux+placebo versus in patients receiving radiotherapy+Erbitux+OTD70DERM® for the treatment of head and neck carcinoma.</brief_summary>
	<brief_title>Trial of OTD70DERM® in Radio-dermatitis Induced by Radiotherapy-Erbitux®</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Radiodermatitis</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Head and neck carcinoma treated by radiotherapy (70Gy) plus Erbitux IMRT; Concomitant chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Head and neck carcinoma treated by radiotherapy plus erbitux</keyword>
</DOC>